galantamine Side Effects
Also known as: Razadyne
Analysis of 1,577 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
1,577
Death-Related
191
12.1% of reports
Hospitalizations
810
51.4% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 191 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 53 |
| DRUG INEFFECTIVE | 31 |
| OFF LABEL USE | 25 |
| CONDITION AGGRAVATED | 21 |
| CARDIAC ARREST | 17 |
| FALL | 15 |
| PARKINSON^S DISEASE | 12 |
| CONFUSIONAL STATE | 11 |
| ASTHENIA | 10 |
| DEHYDRATION | 10 |
| DRUG INEFFECTIVE FOR UNAPPROVED INDICATION | 10 |
| FATIGUE | 10 |
| SUDDEN DEATH | 10 |
| TOXICITY TO VARIOUS AGENTS | 10 |
| DECREASED APPETITE | 9 |
| HALLUCINATION | 9 |
| DRUG INTERACTION | 8 |
| MALAISE | 8 |
| OVERDOSE | 8 |
| ABDOMINAL PAIN | 7 |
Reactions in Hospitalization Reports
Top reactions in 810 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| FALL | 337 |
| COGNITIVE DISORDER | 290 |
| HYPOTENSION | 278 |
| ORTHOSTATIC HYPOTENSION | 276 |
| CONSTIPATION | 272 |
| BALANCE DISORDER | 267 |
| SEDATION | 254 |
| DEPRESSED LEVEL OF CONSCIOUSNESS | 240 |
| TOXICITY TO VARIOUS AGENTS | 234 |
| SEDATION COMPLICATION | 232 |
| CREATININE RENAL CLEARANCE DECREASED | 228 |
| PAIN | 228 |
| BLOOD CALCIUM DECREASED | 227 |
| MOBILITY DECREASED | 220 |
| OFF LABEL USE | 73 |
| DRUG INTERACTION | 71 |
| DYSPNOEA | 68 |
| OVERDOSE | 60 |
| PRODUCT USE IN UNAPPROVED INDICATION | 45 |
| RENAL FUNCTION TEST ABNORMAL | 43 |
Nearby — Related Medications
What the FAERS Data Reveals About galantamine Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 1,577 voluntary reports linked to galantamine and its brand equivalents (Razadyne), spanning 2004 through 2025. Of those, 191 (12.1%) listed death as an outcome and 810 (51.4%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 60% were female and 39% male; age distribution skews toward 75+, with 811 reports in that bracket. The single most reported reaction is fall with 375 submissions, followed by cognitive disorder and constipation.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.